# A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI

> **NCT01763307** · PHASE2 · COMPLETED · sponsor: **Hadassah Medical Organization** · enrollment: 18 (actual)

## Conditions studied

- Rash Due to Epidermal Growth Factor Receptor Inhibitors

## Interventions

- **DRUG:** RECONVAL CREAM
- **DRUG:** PLACEBO

## Key facts

- **NCT ID:** NCT01763307
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-01
- **Final completion:** 2018-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01763307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01763307, "A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01763307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*